Crinetics Pharmaceuticals (CRNX) Cash from Operations (2017 - 2026)

Crinetics Pharmaceuticals' Cash from Operations history runs 10 years deep, the most recent figure standing at 124703000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 40.98% year-over-year to 124703000.0 in Q1 2026; TTM through Mar 2026 was 414173000.0, a 55.83% decrease from a year earlier, with the FY2025 full-year figure at 377922000.0, down 64.18% from the prior year.
• Cash from Operations declined to 124703000.0 in Q1 2026 per CRNX's latest filing, from 92901000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 13543000.0 in Q1 2022 and bottomed at 124703000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 47644000.0 (2024), against an average of 59801294.12.
• Across the five-year window, Cash from Operations jumped 32.51% in 2022 and sank 200.66% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 35207000.0 in 2022, then fell by 15.9% to 40806000.0 in 2023, then plunged by 63.88% to 66871000.0 in 2024, then tumbled by 38.93% to 92901000.0 in 2025, then tumbled by 34.23% to 124703000.0 in 2026.
• Per Business Quant, the three latest CRNX Cash from Operations figures stand at 124703000.0 (Q1 2026), 92901000.0 (Q4 2025), and 110718000.0 (Q3 2025).